Dr Reddy’s to spend $400 million for R&D

07 Apr 2014 Evaluate

Dr Reddy’s Laboratories is planning to spend around $400 million on research and development (R&D) over 3-4 years in biologics and proprietary products. The company had 21 active products in the proprietary products pipeline, of which six were in clinical development stage as on March 31, 2013.

Moreover, the drugs currently in clinical development stage are targeted in the areas of cardiovascular disorders, psoriasis, pain, anti-infective atopic dermatitis/ psoriasis and migraine. The new drug research on metabolic disorders/ cardiovascular disorders is in Phase-II while the remaining five drugs are in the clinical stage.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1240.00 4.85 (0.39%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×